TrialLancet (London, England)2023

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.

Neeraj Agarwal et al.PubMed ↗Publisher ↗

No numbers read from the abstract.